Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Tetra BioPharma
Deal Size : Undisclosed
Deal Type : Partnership
Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna
Details : The registration and commercialization of Tetra's various prescription products (REDUVO™ AdVersa®, QIXLEEF™ and CAUMZ™) across Avicanna's channels in Latin/South America. This opens the door for Tetra to initiate sales earlier than planned.
Product Name : Reduvo Adversa
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 14, 2022
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Tetra BioPharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Tetra BioPharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Tetra will use the Adversa® technology to develop a THC-based mucoadhesive film containing its PPP-002 (Dronabinol) drug candidate for the treatment of chemotherapy-induced nausea and vomiting.
Product Name : PPP-002
Product Type : Controlled Substance
Upfront Cash : Undisclosed
October 21, 2020
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Tetra BioPharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Thylakoid extract
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Devonian announced that the US Patent and Trademark Office has issued a Notice of Allowance for patent titled “Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease" covering the use of Thykamine™ for the treat...
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : Thylakoid extract
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable